{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106651","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.844771+00:00","generated_at":"2026-06-10T04:40:24.594064+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Ocular Therapeutix CEO presents OTX-TKI program at EURETINA conference","bullets":["CEO Antony Mattessich presented on OTX-TKI for wet AMD at EURETINA Innovation Spotlight on Oct 4, 2023.","Presentation provided an overview of the investigational tyrosine kinase inhibitor therapy for retinal vascular diseases.","No new clinical data, financial guidance, or material updates were disclosed in the slides."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106651","json":"https://secwatch.observer/filing/0001104659-23-106651.json","markdown":"https://secwatch.observer/filing/0001104659-23-106651.md","text":"https://secwatch.observer/filing/0001104659-23-106651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/0001104659-23-106651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/tm2327605d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:40:24.594064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}